Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / BRSCW Application: Lokshin - Univ of Pitts (2008)

BRSCW Application: Lokshin - Univ of Pitts (2008)

288
TgII, SCC, HSP 70, IGFBP-1,2, GH, sICAM-1, MMP-9, MPO, tPAI-1, CA72-4, CA15-3, EGFR, Osteopontin (OPN), Endostatin (RNDO), Thrombospondin (THBS), Angiostatin (ANGIO), Apolipoproteins (Apo) A1, A2, B, E), Resistin, and PAI-1
Case/control
Proteomics
Breast and Gynecologic Cancers Research

One KLK,(KLK6) ranked 6th among all tested biomarkers(approx.50)

1.   Validation of ovarian cancer biomarkers (pre- and post-menopausal women) 2.   Validation of breast cancer biomarkers
Luminex

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


News

Maintenance Notice: EDRN applications undergoing maintenance 2014-09-15 through the 16th. During this time, logins to this site will be unavailable.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html